Searching for the next 'big hairy goal,' BlueRock CEO Emile Nuwaysir jumps to in vivo cell therapy startup Ensoma
Two years after Bayer swallowed the remaining shares of his regenerative cell therapy company, Emile Nuwaysir has found himself a new “big hairy goal”: in vivo cell therapy.
Ensoma, an ambitious and well-backed startup out of Fred Hutch and the University of Washington, has tapped Nuwaysir as the new CEO. It’ll be the serial executive’s second stint as a CEO after BlueRock, where he shepherded a first-of-its-kind cell therapy for Parkinson’s disease into clinical trials.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.